PureTech Health plc (PRTC)
NASDAQ: PRTC · Real-Time Price · USD
18.05
+1.26 (7.50%)
At close: Dec 5, 2025, 4:00 PM EST
17.70
-0.35 (-1.94%)
After-hours: Dec 5, 2025, 7:24 PM EST
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
$114,125
Profits / Employee
$904,964
Market Cap
392.85M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRTC News
- 1 day ago - PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Business Wire
- 6 weeks ago - PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group - Business Wire
- 2 months ago - PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF - Business Wire
- 3 months ago - PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 3 months ago - PureTech Health plc – Half-Year Report - Business Wire
- 3 months ago - PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF - Business Wire
- 3 months ago - PureTech Health: Notice of Half-Yearly Results - Business Wire
- 4 months ago - PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint - Business Wire